Fosun: Wholly-owned subsidiary intends to jointly invest in Chaohexi No.2 fund with professional institutions.

Fosun Pharma announced that on June 17, 2026, the company convened the second special meeting of the sixth independent directors of the board of directors in 2026 to review and approve the "Proposal on the Joint Investment of Whetstone II Fund by a Wholly-Owned Subsidiary and a Professional Institution and the Related Transaction". The company's wholly-owned subsidiary, Hainan Fosun Pharma Investment, intends to jointly invest in the Whetstone II Fund with the spouse of the company's controlling shareholder, Liu Bing, and a professional institution. Because Liu Bing directly holds 43.7% of the shares, this investment constitutes a related party transaction. The related directors, including Liu Bing, abstained from voting, the decision-making process was compliant, and there is no situation that harms the interests of the company and shareholders.